

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

### Two new *neo*-clerodane diterpenoid alkaloids from *Scutellaria barbata* with cytotoxic activities

Sheng-Jun Dai<sup>a</sup>; Wei-Bing Peng<sup>b</sup>; Li Shen<sup>b</sup>; De-Wu Zhang<sup>a</sup>; Yan Ren<sup>a</sup>

<sup>a</sup> School of Pharmaceutical Science, Yantai University, Yantai, China <sup>b</sup> Key Laboratory of Marine Drugs, Chinese Ministry of Education, Institute of Marine Drug and Food, Ocean University of China, Qingdao, China

**To cite this Article** Dai, Sheng-Jun , Peng, Wei-Bing , Shen, Li , Zhang, De-Wu and Ren, Yan(2009) 'Two new *neo*-clerodane diterpenoid alkaloids from *Scutellaria barbata* with cytotoxic activities', *Journal of Asian Natural Products Research*, 11: 5, 451 – 456

**To link to this Article:** DOI: 10.1080/10286020902845652

URL: <http://dx.doi.org/10.1080/10286020902845652>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## Two new *neo*-clerodane diterpenoid alkaloids from *Scutellaria barbata* with cytotoxic activities

Sheng-Jun Dai<sup>a\*</sup>, Wei-Bing Peng<sup>b</sup>, Li Shen<sup>b</sup>, De-Wu Zhang<sup>a</sup> and Yan Ren<sup>a</sup>

<sup>a</sup>School of Pharmaceutical Science, Yantai University, Yantai 264005, China; <sup>b</sup>Key Laboratory of Marine Drugs, Chinese Ministry of Education, Institute of Marine Drug and Food, Ocean University of China, Qingdao 266003, China

(Received 18 December 2008; final version received 23 February 2009)

Two new *neo*-clerodane diterpenoid alkaloids, scutebarbatine O (**1**) and 6-*O*-nicotinoylscutebarbatine G (**2**), were isolated from the whole plant of *Scutellaria barbata*. Their structures were elucidated by spectroscopic methods including extensive 1D and 2D NMR analyses. *In vitro*, compounds **1** and **2** showed cytotoxic activities against three human tumor cell lines, namely, HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma cells, and with IC<sub>50</sub> values in the range of 2.1–5.7 μM.

**Keywords:** *Scutellaria barbata* D. Don; *neo*-clerodane diterpenoid alkaloid; scutebarbatine O; 6-*O*-nicotinoylscutebarbatine G; cytotoxic activity

### 1. Introduction

The traditional Chinese medicinal herb ‘Banzhilian’, derived from the dry whole plant of *Scutellaria barbata* D. Don (Labiatae), is commonly used for the treatment of tumors, hepatitis, cirrhosis, and other diseases [1]. In our previous phytochemical studies on *S. barbata*, we reported the isolation of *neo*-clerodane diterpenoid alkaloids [2–6], which showed significant cytotoxic activities. As a continuous search for more novel *neo*-clerodane diterpenoid alkaloid, we have further investigated the aerial parts of this species and isolated two new *neo*-clerodane diterpenoid alkaloids, scutebarbatine O (**1**) and 6-*O*-nicotinoylscutebarbatine G (**2**). By means of detailed spectroscopic methods, the structures of two new compounds **1** and **2** were elucidated. In addition, the two new compounds were screened for

cytotoxicity against three tumor cell lines (HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma cells), with IC<sub>50</sub> values being in the range of 2.1–5.7 μM. Herein we report on the isolation, structure elucidation, as well as the evaluation of cytotoxic effects of these two new *neo*-clerodane diterpenoid alkaloids.

### 2. Results and discussion

Compound **1** was obtained as white needles, and showed positive response to alkaloid reagents. The molecular formula was established as C<sub>32</sub>H<sub>34</sub>N<sub>2</sub>O<sub>8</sub> by HR-FAB mass spectrum, which displayed a quasi-molecular ion at *m/z* 575.2398 [M + H]<sup>+</sup>. The IR spectrum showed absorption bands at 3347, 1777, 1740, 1717, 1633, 1604, 1482, and 1388 cm<sup>-1</sup>, which were assignable to hydroxyl, conjugated carbonyl,

\*Corresponding author. Email: daishengjun\_9@hotmail.com

$\alpha,\beta$ -unsaturated  $\gamma$ -lactone, and aromatic ring groups. The  $^1\text{H}$  NMR spectrum of **1** revealed the presence of the following fragments: three tertiary methyl groups at  $\delta$  1.09 (3H, s, H-17), 1.28 (3H, s, H-20), and 1.54 (3H, s, H-19); an  $\alpha,\beta$ -unsaturated  $\gamma$ -lactone moiety at  $\delta$  5.96 (1H, br s, H-14) and 5.00 (2H, br s, H-16); a double bond with *E*-configuration at  $\delta$  6.34 (1H, d,  $J = 16.8$  Hz, H-11) and 6.45 (1H, d,  $J = 16.8$  Hz, H-12); two nicotinic acid ester moieties at  $\delta$  9.08 (1H, br s, H-3'), 8.98 (1H, br s, H-3''), 8.65 (1H, br d,  $J = 4.6$  Hz, H-5'), 8.73 (1H, br d,  $J = 4.6$  Hz, H-5''), 7.23 (1H, dd,  $J = 4.6, 7.8$  Hz, H-6'), 7.31 (1H, dd,  $J = 4.6, 7.7$  Hz, H-6''), 8.14 (1H, br d,  $J = 7.8$  Hz, H-7'), and 8.03 (1H, br d,  $J = 7.7$  Hz, H-7''); a terminal double bond group at  $\delta$  4.96 (1H, br s, H<sub>a</sub>-18) and 5.03 (1H, br s, H<sub>b</sub>-18); and an oxygenated methenyl group at  $\delta$  4.58 (1H, dd,  $J = 4.8, 11.7$  Hz, H-3). In addition, the  $^1\text{H}$ - $^1\text{H}$  COSY experiment revealed two spin systems. The first spin system included the signals of a methine ( $\delta$  2.11, 1H, dd,  $J = 2.3, 12.0$  Hz, H-10), two methylenes ( $\delta$  1.28, 1H, m, H<sub>a</sub>-1; 2.15, 1H, m, H<sub>b</sub>-1; 1.52, 1H, m, H<sub>a</sub>-2; 1.79, 1H, m, H<sub>b</sub>-2), and an oxygenated methine ( $\delta$  4.58, dd,  $J = 4.8, 11.7$  Hz, H-3). Thus, H<sub>a</sub>-1 and H<sub>b</sub>-1 coupled with the signals of H-10, H<sub>a</sub>-2, and H<sub>b</sub>-2 which in turn was vicinally coupled with

H-3. The latter, together with the crucial long-range correlations observed in the HMBC spectrum of **1** (Figure 1), indicated the presence of the hydroxyl group at C-3. The second spin system was traced from two aliphatic protons on oxygenated carbons at  $\delta$  6.29 (1H, d,  $J = 9.8$  Hz, H-6) and 5.81 (1H, d,  $J = 9.8$  Hz, H-7). Observation of the cross-peaks in the HMBC spectrum from H-6 to C-1' and from H-7 to C-1'' proved that two nicotinic acid ester moieties were connected to C-6 and C-7, respectively. Based on the above data and comprehensive 2D NMR experiments ( $^1\text{H}$ - $^1\text{H}$  COSY, HMQC, and HMBC), the structure of **1** was established as shown in Figure 1. The relative stereochemistry of the chiral centers in **1** was resolved by 2D ROESY data. In the ROESY spectrum (Figure 1), the cross-peaks were observed from H-6 to H-10, from H<sub>3</sub>-20 to H-7, H<sub>3</sub>-17, and H<sub>3</sub>-19, as well as from H-7 to H<sub>3</sub>-17, H<sub>3</sub>-19, and H<sub>3</sub>-20. Therefore, H<sub>3</sub>-17, H<sub>3</sub>-19, H<sub>3</sub>-20, and H-7 were on the same molecular plane ( $\alpha$ -configuration), while H-6 and H-10 were on the opposite side of the molecular plane ( $\beta$ -configuration). Furthermore, the resonance of H-3 was not enhanced by irradiation of H<sub>3</sub>-19, indicating  $\beta$ -configuration of H-3. Thus, based on the above analysis, the structure of compound **1** was confirmed as shown in Figure 2.




Figure 1. Key HMBC and ROESY correlations of **1**.




Figure 2. Structures of compounds **1** and **2**.

Compound **2** was isolated and purified as white needles. In the HR-FAB mass spectrum, **2** gave a quasi-molecular ion peak at  $m/z$  577.2553  $[M + H]^+$ , corresponding to a molecular formula  $C_{32}H_{36}N_2O_8$ . The IR spectrum showed absorption bands at 3344, 1780, 1735, 1629, 1596, 1500, 1472, and  $1388\text{ cm}^{-1}$ , which were assignable to hydroxyl, conjugated carbonyl, aromatic ring, and  $\gamma$ -lactone groups. Comparison of its  $^1\text{H}$  and  $^{13}\text{C}$  NMR data (Table 1) with those of scutebarbatine G showed that **2** had many spectral features in common with scutebarbatine G [3]. The differences in their NMR spectra could be accounted for the change of attachment of the hydroxyl group. Instead, a nicotinic acid ester moiety ( $\delta_{\text{H}}$  9.27, 1H, br s; 8.80, 1H, br d,  $J = 4.5\text{ Hz}$ ; 7.43, 1H, dd,  $J = 4.5, 7.6\text{ Hz}$ ; 8.35, 1H, br d,  $J = 7.6\text{ Hz}$ ; and  $\delta_{\text{C}}$  165.6, 126.0, 150.8, 153.7, 123.6, 137.1) was attached to C-6 in **2**. The stereochemical assignments of the chiral centers in **2** were accomplished in the similar manner as described for scutebarbatine G, with H<sub>3</sub>-17, H<sub>3</sub>-19, H<sub>3</sub>-20, H-7, H-11, and H<sub>B</sub>-16 being on the  $\alpha$ -configuration, while H-6 and H-10 being on the  $\beta$ -configuration (Figure 3).

The two isolated compounds (**1** and **2**) were evaluated for their cytotoxic activities against HONE-1, KB, and HT29

tumor cell lines using methylene blue dye assay and anti-cancer drugs, etoposide and cisplatin [7,8] as positive controls. These compounds exhibited cytotoxicity as shown in Table 2.

### 3. Experimental

#### 3.1 General experimental procedures

Melting points were measured on an XT-4 micro-melting point apparatus and are uncorrected. Optical rotations were measured on a Perkin-Elmer 241 polarimeter. UV spectra were obtained on a Shimadzu UV-160 spectrophotometer. IR spectra were recorded on a Perkin-Elmer 683 infrared spectrometer with KBr disks. FAB-MS and HR-FAB-MS were recorded on an Autospec-Ultima ETOF MS spectrometer. NMR spectra were recorded on a Bruker Avance 400 spectrometer at 400 MHz ( $^1\text{H}$ ) and 100 MHz ( $^{13}\text{C}$ ), with TMS as the internal standard. Silica gel (200–300 mesh) for column chromatography and silica gel GF254 for preparative TLC were obtained from Qingdao Marine Chemical Factory, Qingdao, China.

#### 3.2 Plant material

*S. barbata* D. Don was collected in Linyi District, Shandong Province, China, in

Table 1.  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectral data of compounds **1** and **2** (in  $\text{CDCl}_3$ )<sup>a,b</sup>.

No.	<b>1</b>		<b>2</b>	
	$\delta_{\text{H}}$	$\delta_{\text{C}}$	$\delta_{\text{H}}$	$\delta_{\text{C}}$
1	1.28 (m, $\text{H}_{\text{a}-1}$ ), 2.15 (m, $\text{H}_{\text{b}-1}$ )	32.1 $\text{CH}_2$	1.65 (m, $\text{H}_{\text{a}-1}$ ), 2.01 (m, $\text{H}_{\text{b}-1}$ )	28.5 $\text{CH}_2$
2	1.52 (m, $\text{H}_{\text{a}-2}$ ), 1.79 (m, $\text{H}_{\text{b}-2}$ )	21.5 $\text{CH}_2$	2.76 (m, 2H)	32.7 $\text{CH}_2$
3	4.58 (dd, 4.8, 11.7)	82.4 CH	5.36 (br s)	120.1 CH
4		151.6 C		143.7 C
5		46.4 C		44.2 C
6	6.29 (d, 9.8)	74.4 CH	5.44 (d, 10.0)	77.1 CH
7	5.81 (d, 9.8)	76.0 CH	3.71 (d, 10.0)	74.6 CH
8		77.2 C		82.1 C
9		48.5 C		38.4 C
10	2.11 (dd, 2.3, 12.0)	46.0 CH	2.74 (dd, 2.4, 12.2)	43.6 CH
11	6.34 (d, 16.8)	145.5 CH	5.79 (dd, 3.9, 12.0)	72.1 CH
12	6.45 (d, 16.8)	122.2 CH	1.68 (m, $\text{H}_{\text{a}-12}$ ), 2.03 (m, $\text{H}_{\text{b}-12}$ )	29.1 $\text{CH}_2$
13		161.6 C		76.3 C
14	5.96 (br s)	115.6 CH	2.58 (d, 17.0, $\text{H}_{\text{a}-14}$ ), 2.79 (d, 17.0, $\text{H}_{\text{b}-14}$ )	42.4 $\text{CH}_2$
15		173.8 C		174.3 C
16	5.00 (br s, 2H)	70.6 $\text{CH}_2$	4.25 (d, 8.7, $\text{H}_{\text{a}-16}$ ), 4.44 (d, 8.7, $\text{H}_{\text{b}-16}$ )	79.5 $\text{CH}_2$
17	1.09 (s, 3H)	22.5 $\text{CH}_3$	1.12 (s, 3H)	21.8 $\text{CH}_3$
18	4.96 (br s, $\text{H}_{\text{a}-18}$ ), 5.03 (br s, $\text{H}_{\text{b}-18}$ )	102.2 $\text{CH}_2$	1.69 (s, 3H)	20.4 $\text{CH}_3$
19	1.54 (s, 3H)	17.3 $\text{CH}_3$	1.46 (s, 3H)	16.3 $\text{CH}_3$
20	1.28 (s, 3H)	15.2 $\text{CH}_3$	1.40 (s, 3H)	20.3 $\text{CH}_3$
1'		164.8 C		165.6 C
2'		125.5 C		126.0 C
3'	9.08 (br s)	150.1 CH	9.27 (br s)	150.8 CH
5'	8.65 (br d, 4.6)	153.9 CH	8.80 (br d, 4.5)	153.7 CH
6'	7.23 (dd, 4.6, 7.8)	123.2 CH	7.43 (dd, 4.5, 7.6)	123.6 CH
7'	8.14 (br d, 7.8)	137.1 CH	8.35 (br d, 7.6)	137.1 CH
1''		164.6 C		164.4 C
2''		125.1 C		126.5 C
3''	8.98 (br s)	150.7 CH	9.17 (br s)	150.6 CH
5''	8.73 (br d, 4.6)	153.6 CH	8.83 (br d, 4.5)	153.5 CH
6''	7.31 (dd, 4.6, 7.7)	123.3 CH	7.46 (dd, 4.5, 7.7)	123.5 CH
7''	8.03 (br d, 7.7)	136.9 CH	8.27 (br d, 7.7)	137.4 CH

<sup>a</sup> Coupling constants (in Hz) were presented in parentheses.


<sup>b</sup> The assignments were based on DEPT, HMQC, HMBC, and  $^1\text{H}$ - $^1\text{H}$  COSY experiments.

September 2006, and identified by Prof. Yan-Yan Zhao, School of Pharmaceutical Science, Yantai University. The whole plants of *S. barbata* were harvested and air-dried at room temperature in the dark. A voucher specimen (YP03063) has been deposited at the Herbarium of

School of Pharmaceutical Science, Yantai University.

### 3.3 Extraction and isolation

The air-dried whole plant (30 kg) of *S. barbata* was finely cut and extracted

Figure 3. Key HMBC and ROESY correlations of **2**.Table 2. Cytotoxicity of compounds **1** and **2** against cultured HONE-1, KB, and HT29 cancer cell lines.

Compounds	Growth inhibition constant (IC <sub>50</sub> ) <sup>a</sup> (μM)		
	HONE-1	KB	HT29
Etoposide <sup>b</sup>	1.1 ± 0.7	1.3 ± 0.2	1.6 ± 0.6
Cisplatin <sup>b</sup>	2.3 ± 1.5	2.8 ± 0.9	3.9 ± 1.2
<b>1</b>	2.9 ± 1.5	2.2 ± 1.8	4.3 ± 2.3
<b>2</b>	3.1 ± 1.4	2.1 ± 3.0	5.7 ± 1.8

<sup>a</sup> IC<sub>50</sub> is defined as the concentration that resulted in a 50% decrease in cell number and the results are means ± SD of the three independent replicates. The IC<sub>50</sub> greater than 10 μM was considered to be no cytotoxicity.

<sup>b</sup> Positive control substance.

three times with refluxing EtOH. Evaporation of the solvent under reduced pressure provided the ethanolic extract. The extract (1.2 kg) was dissolved and suspended in H<sub>2</sub>O, and partitioned with CHCl<sub>3</sub> and EtOAc. The CHCl<sub>3</sub> fraction (179.8 g) was subjected to extraction with 3% HCl. Following this, the aqueous solution was adjusted with NH<sub>4</sub>OH to pH 10 and extracted with CHCl<sub>3</sub>. The organic fractions were combined, and the solvent was evaporated under vacuum to yield the CHCl<sub>3</sub> alkaloidal fraction (48.3 g). The alkaloidal fraction (47.1 g) was initially subjected to column chromatography on silica gel, eluted with cyclohexane–acetone (95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 60:40, and 50:50) to give eight fractions. Fraction 7 (2.4 g) was separated by reversed-phase silica gel (150 g, 40–50 μm) column chromatography (eluted by MeOH–H<sub>2</sub>O, 55:45, v/v) and purified on

Sephadex LH-20 (100 g, eluting with CHCl<sub>3</sub>–CH<sub>3</sub>OH, 10:40, v/v) to afford **1** (33 mg) and **2** (28 mg).

### 3.3.1 Scutebarbatine O (**1**)

White needles; mp 150–151°C, [α]<sub>D</sub><sup>29</sup> –107.3 (*c* = 0.13, CHCl<sub>3</sub>). UV (CHCl<sub>3</sub>) λ<sub>max</sub> 220 and 260 nm. IR (KBr) ν<sub>max</sub> 3347, 1777, 1740, 1717, 1633, 1604, 1482, and 1388 cm<sup>-1</sup>. FAB-MS *m/z* 575.3 [M + H]<sup>+</sup>. HR-FAB-MS *m/z* 575.2398 [M + H]<sup>+</sup> (calcd for C<sub>32</sub>H<sub>35</sub>N<sub>2</sub>O<sub>8</sub>, 575.2393). For <sup>1</sup>H and <sup>13</sup>C NMR spectral data, see Table 1.

### 3.3.2 6-O-nicotinoylscutebarbatine G (**2**)

White needles; mp 151–153°C, [α]<sub>D</sub><sup>29</sup> –87.6 (*c* = 0.14, CHCl<sub>3</sub>). UV (CHCl<sub>3</sub>) λ<sub>max</sub> 221 and 259 nm. IR (KBr) ν<sub>max</sub> 3344, 1780, 1735, 1629, 1596, 1500, 1472, and

1388  $\text{cm}^{-1}$ . FAB-MS  $m/z$  577.4  $[\text{M} + \text{H}]^+$ . HR-FAB-MS  $m/z$  577.2553  $[\text{M} + \text{H}]^+$  (calcd for  $\text{C}_{32}\text{H}_{37}\text{N}_2\text{O}_8$ , 577.2550). For  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectral data, see Table 1.

### 3.4 Antitumoral cytotoxic bioassays

Human nasopharyngeal carcinoma HONE-1, oral epidermoid carcinoma KB, and colorectal carcinoma HT29 cells were maintained in RPMI-1640 medium supplied with 5% fetal bovine serum. Cells in logarithmic phase were cultured at a density of 5000 cells/ml per well in a 24-well plate. The cells were exposed to various concentrations of the tested drugs for 72 h. The methylene blue dye assay was used to evaluate the effects of the tested drugs on cell growth, as described previously [9]. The  $\text{IC}_{50}$  value resulted from 50% inhibition of cell growth was calculated graphically as a comparison with the control.

### Acknowledgements

We are grateful to Mr Yong Li, Ji-Yong Chen, and Ms Hong Yu (School of Pharmaceutical

Science, Yantai University) for the measurement of FAB-MS, HR-FAB-MS, UV, IR, and NMR spectra, respectively. We also gratefully acknowledge Mr Zhen-Hua Wang and Ms Ming Yang (School of Pharmaceutical Science, Yantai University) for the bioactivity screenings.

### References

- [1] Z.Q. Wang, F.M. Xu, X.Z. Yan, and Y. Zhu, *Chin. Chem. Lett.* **7**, 333 (1996).
- [2] S.J. Dai, M. Chen, K. Liu, Y.T. Jiang, and L. Shen, *Chem. Pharm. Bull.* **54**, 869 (2006).
- [3] S.J. Dai, J.Y. Tao, K. Liu, Y.T. Jiang, and L. Shen, *Phytochemistry* **67**, 1326 (2006).
- [4] S.J. Dai, G.F. Wang, M. Chen, K. Liu, and L. Shen, *Chem. Pharm. Bull.* **55**, 1218 (2007).
- [5] S.J. Dai, J.Y. Sun, Y. Ren, K. Liu, and L. Shen, *Planta Med.* **73**, 1217 (2007).
- [6] S.J. Dai, D.D. Liang, Y. Ren, K. Liu, and L. Shen, *Chem. Pharm. Bull.* **56**, 207 (2008).
- [7] J.Y. Chang, J.F. Liu, S.H. Juang, T.W. Liu, and L.T. Chen, *Cancer Res.* **62**, 3716 (2002).
- [8] C.I. Chang, C.C. Kuo, J.Y. Chang, and Y.H. Kuo, *J. Nat. Prod.* **67**, 91 (2004).
- [9] J.Y. Chang, C.Y. Chang, C.C. Kuo, L.T. Chen, Y.S. Wei, and Y.H. Kuo, *Mol. Pharmacol.* **65**, 77 (2004).